KTTA vs. ADXS, VCNX, CANF, TRVN, CVKD, PULM, HEPA, ADIL, TFFP, and ASLN
Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Ayala Pharmaceuticals (ADXS), Vaccinex (VCNX), Can-Fite BioPharma (CANF), Trevena (TRVN), Cadrenal Therapeutics (CVKD), Pulmatrix (PULM), Hepion Pharmaceuticals (HEPA), Adial Pharmaceuticals (ADIL), TFF Pharmaceuticals (TFFP), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
Pasithea Therapeutics (NASDAQ:KTTA) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 14.1% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Pasithea Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.
Pasithea Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals.
Pasithea Therapeutics' return on equity of -49.04% beat Ayala Pharmaceuticals' return on equity.
Pasithea Therapeutics received 2 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 40.00% of users gave Pasithea Therapeutics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Summary
Pasithea Therapeutics beats Ayala Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get Pasithea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pasithea Therapeutics Competitors List
Related Companies and Tools
